L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure

GIORGIO VESCOVO,1 BARBARA RAVARA,2 VALERIO GOBBO,2 MARCO SANDRI,2 ANNALISA ANGELINI,3 MILA DELLA BARBERA,3 MASSIMO DONA,2 GIANFRANCO PELUSO,4 MENOTTI CALVANI,5 LUIGI MOSCONI,5 AND LUCIANO DALLA LIBERA2

1Internal Medicine, City Hospital, 45011 Adria; 2Consiglio Nazionale delle Ricerche Institute of Neuroscience, Unit for Muscle Biology and Pathophysiology, Department of Biomedical Sciences, and 3Department of Cardiovascular Pathology, University of Padua, 35100 Padua; 4Department of Experimental Oncology, National Cancer Institute, 80072 Naples; 5Scientific Department, Sigma Tau, 00040 Rome, Italy

Received 29 January 2002; accepted in final form 17 May 2002

L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol 283: C802–C810, 2002. First published May 22, 2002; 10.1152/ajpcell.00046.2002.—Skeletal muscle in congestive heart failure is responsible for increased fatigability and decreased exercise capacity. A specific myopathy with increased expression of fast-type myosins, myocyte atrophy, secondary to myocyte apoptosis triggered by high levels of circulating tumor necrosis factor-α (TNF-α) has been described. In an animal model of heart failure, the monocrotaline-treated rat, we have observed an increase of apoptotic skeletal muscle nuclei. Proapoptotic agents, caspase-3 and -9, were increased, as well as serum levels of TNF-α and its second messenger sphingosine. Treatment of rats with L-carnitine, known for its protective effect on muscle metabolism injuries, was found to inhibit caspasas and to decrease the levels of TNF-α and sphingosine, as well as the number of apoptotic myonuclei. Staurosporine was used in in vitro experiments to induce apoptosis in skeletal muscle cells in culture. When L-carnitine was applied to skeletal muscle cells, before staurosporine treatment, we observed a reducton in apoptosis. These findings show that L-carnitine can prevent apoptosis of skeletal muscles cells and has a role in the treatment of congestive heart failure-associated myopathy.

tumor necrosis factor; sphingosine; caspasas; staurosporine

HEART FAILURE IS CHARACTERIZED by a decreased exercise capacity with early appearance of fatigue and dyspnea (15, 18). These symptoms are due in part to a skeletal muscle myopathy with atrophy, which is responsible for the decreased muscle strength and endurance (18, 35), and shift from the “slow, fatigue resistant” type I to the “fast, fatigable” type II fibers (31, 30, 29), which in turn causes the increased muscle fatigability (29). Apoptosis has been shown to be one of the major determinants of skeletal muscle atrophy (7, 34, 33), and its magnitude correlates with the severity of the syndrome (33). Myocyte death is triggered by cytokine activation, which is almost always present in heart failure as a sign of a chronic inflammatory state (13, 14). Cytokines, such as tumor necrosis factor-α (TNF-α), can induce apoptosis either directly or through secondary messengers, such as the sphingolipid sphingosine (SPH) (10, 13, 22). We have also shown that SPH serum levels are increased in heart failure in parallel with TNF-α and that this molecule is able to induce skeletal myocyte apoptosis both in vivo and in vitro (6, 25). Although clinical trials aimed to block TNF-α with specific antibodies such as infliximab or etanercept have failed (17), there is compelling evidence that apoptosis can be inhibited, with favorable consequences on muscle atrophy. This can be achieved for instance by blocking the angiotensin II (ANG II) receptors (4). L-Carnitine is a quaternary amine that is fundamental in skeletal muscle metabolism, in that it is the compulsory step for cell death execution (2, 21). Moreover, it has been shown that L-carnitine prevents doxorubicin-induced apoptosis in cardiac myocytes, by inhibiting the doxorubicin-induced sphingomyelin hydrolysis and ceramide generation (2). It seems therefore likely that sphingolipids play a determinant role

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
in inducing apoptosis in the skeletal muscle, and it could be argued that programmed cell death may be stopped by blocking the sphingolipid activation cascade. In this study, we tried to block sphingolipid formation and prevent apoptosis in a well-known model of heart failure, the monocrotaline-treated rat, by giving l-carnitine. The ultimate aim of this approach was to prevent the development of muscle atrophy, which we all know is one of the major determinants of exercise capacity (18, 35), and to give a clue for the understanding of the pathophysiology of the heart failure myopathy, which in turn may have future implications in the development of further treatment for heart failure.

**MATERIALS AND METHODS**

**In Vivo Study**

**Experimental model.** Four groups of animals were studied for a total of 56 animals. Thirty-six male (80–100 g) Sprague-Dawley rats had congestive heart failure (CHF) induced by monocrotaline (Sigma, St. Louis, MO). This alkaloid produces severe pulmonary hypertension followed by right ventricular failure (4, 34) without inducing by itself changes in skeletal muscle myosin heavy chain (MHC) composition and apoptosis (28). Monocrotaline was injected intraperitoneally in the rats at the dose of 30 mg/kg. Starting at the same day, 26 out of 36 rats were treated with 50 mg·kg⁻¹·die⁻¹ l-carnitine (Sigma Tau, Rome, Italy) given in drinking water (CHFCar); 10 rats therefore formed the CHF group. Rats were kept in single cages, and the water that had been drunk was measured daily. The other 10 additional rats had only l-carnitine in drinking water, and they formed the l-carnitine control group (ConCar). Ten age- and diet-matched rats were injected with saline and served as controls. After 28 days, when in the monocrotaline-treated animals overt heart failure developed, rats were killed and body, heart, and tibialis anterior weights were measured. Muscles were immediately frozen in liquid nitrogen and stored at −80°C. Hearts were stored in 10% formaldehyde solution. Blood was drawn for SPH, TNF-α, ANG II, aspartate amino transferase (AST), alanine amino transferase (ALT), and l-carnitine measurements.

Experiments were approved by the Biological Ethical Committee of the University of Padua, according to the Italian law.

**Assessment of right ventricle hypertrophy and failure.** To make sure that the monocrotaline-treated animals developed right ventricle failure, beyond the postmortem signs such as pericardial, pleural, and peritoneal effusions (28), the following measurements were taken: right ventricle mass/left ventricle mass (RVM/LVM) and right ventricular mass/right ventricular volume index (RVM/RVV), calculated with a computerized planimeter on photographic pictures of formalin-fixed transverse sections of the heart taken in the middle portion of the interventricular septum (4).

**Electrophoretic separation of MHCs.** We used the method described in details by Vescovo et al. (31, 32). Tibialis anterior muscles were homogenized and solubilized in SDS buffer. Analytical SDS-PAGE was performed on 7% polyacrylamide slabs with 37.5% vol/vol glycerol to separate MHCs (MHC IIa and MHC IIb).

**Assessment of MHC distribution.** The percent distribution of the MHCs was determined by a densitometric scan (Sigma Gel, SPSS, Chicago, IL) after image acquisition of the stained gels (4).

**Single fiber cross-sectional area.** We used single fiber cross-sectional areas (CSA) as an index of myofiber atrophy (4, 6). On each muscle a cross cryosection was taken for histological examination and stained with hematoxylin and eosin. The fiber CSA was calculated with a computerized interactive method (4, 6). At least 400 fibers per specimen were counted at a magnification of ×250 and then averaged.

**Assessment of apoptosis.** In situ DNA nick-end labeling. In situ terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) of fragmented DNA was performed on cryosections using the in situ cell death detection kit POD (Boehringer Mannheim). Labeled nuclei were identified from the negative nuclei counterstained with Hoechst 33258 and were counted after being photographed. The total number of positive nuclei was determined by counting (magnification ×250) all of the labeled nuclei present in the whole specimen. The number of positive nuclei was then expressed as the number of TUNEL-positive nuclei per millimeter cubed (4, 6). TUNEL-positive myofibers and interstitial nuclei were distinguished on the basis of their location on sections stained with laminin, which selectively reacts with the basal lamina. TUNEL-positive nuclei within the basal lamina were taken as myonuclei (4, 6, 7). Separate calculations were made for total TUNEL-positive nuclei and TUNEL-positive myonuclei.

**Tibialis anterior western blot for activated caspase-3 and -9 and BCL-2.** Western blot was performed on 12.5 polyacrylamide gels as previously described (7). Anti-Bcl-2 (29 kDa) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used with anti-rabbit alkaline-phosphatase (Sigma). Anti-cleaved caspase-3 (17 kDa) and anti-cleaved caspase-9 (37 kDa, Cell Signaling Technology, Beverly, MA) were used with anti-rabbit peroxidase-conjugated antibody and revealed by chemiluminescent substrate (SuperSignal West Pico, Pierce, IL).

**Confocal microscopy immunofluorescence.** Frozen sections were incubated for 1 h at room temperature with anti-dystrophin antibody (Novocastra, Newcastle Upon Tyne, UK) diluted 1:300 in 1% BSA, which stains sarcolemma. After three washings with PBS, sections were incubated with anti-mouse IgG FITC-conjugated (Sigma) diluted 1:500 at 37°C for 1 h. The sections were then washed three times with PBS and fixed with 4% paraformaldehyde and incubated with anti-caspase-3 antibody (Cell Signaling Technology) diluted 1:10 overnight at 4°C. Slices were then incubated with anti-rabbit Cy3-conjugated antibody for 1 h at room temperature and analyzed by Bio-Rad (Hercules, CA) confocal microscopy.

**ELISA for apoptosis.** DNA ladder assay was performed according to Yasuhara et al. (36). In brief, 10 muscle cryosections, 20 μm thick, were solubilized in 200 μl of lysis buffer [0.1% Triton X-100, 5 mM Tris·HCl (pH 8.0), 20 mM EGTA, 20 mM EDTA]. Then, polyethylene glycol 8000 and NaCl were added to a final concentration of 2.5% and 1 M, respectively. Samples were centrifuged at 16,000 g for 10 min at 4°C. Protein concentration of supernatant was determined by the method of Bradford and adjusted to 0.01 μg/μl. Cell death ELISA analysis was performed according to manufacturer’s instructions (Boehringer Mannheim). After incubation, the plates were analyzed with a multiwell ELISA reader.

**TNF-α determination.** TNF-α was measured with a solid-phase sandwich ELISA, using a monoclonal antibody specific for rat TNF-α (Euroclone).

**ANG II assay.** ANG II was measured on serum, using an enzyme-immunoassay kit from SPI-BIO (Massy Cedex, France).
SPH determination. For the extraction of sphingolipids, 100- to 300-μl samples of serum were deproteinated by adding warmed butanol (70°C, 800 μl), vortexing, and incubating at 70°C while rocking for 10 min. After sonicating for 1 min, the samples were added to each sample, and the sample was returned to the incubator for 10 min. After sonicating for 1 min, the solutions were separated from the butanol layer by centrifugation at 15,300 g. The upper butanol layer was transferred into a new extraction tube and saponified by the addition of 0.5 M KOH (200 μl). After vortexing, samples were incubated at 70°C while rocking for 1 h with intermittent vortexing and sonicating. HPLC-grade water (400 μl) was added to each sample, and the sample was returned to the incubator for 10 min. After sonicating for 1 min, the layers were separated by centrifuging at 15,300 g for 3 min. The butanol layer was transferred to a new tube and dried down using a Savant (Holbrook, NY) SpeedVac Plus. Dried samples were completely resuspended in methanol (375 μl) and agitated in a bath sonicator for 2 min.

The extracts were then derivatized with o-phthaldehyde (Molecular Probes, Eugene, OR) as previously described (6). The derivatized samples (50-μl injection) were separated on a Bio-Rad Hi-Pore reversed phase column RP-318 (4.6 mm ID × 250 mm) column with a 1.5 cm Perkin-Elmer (Norwalk, CT) NewGuard RP-18 guard column. Samples were run on a Bio-Rad HPLC system with a Perkin-Elmer fluorescence detector (LS-1) (excitation 340 nm, emission 455 nm). The solvent system was methanol, glacial acetic acid, 1 M tetrahydroammonium dihydrogen phosphate, and HPLC-grade water (82.9:1.5:0.9:14.7, vol/vol) run at 1 ml/min.

Carnitine assay. Free carnitine, acylcarnitine, and propionylcarnitine were measured in serum and in muscle homogenate as described by Longo et al. (16). In brief, muscles were homogenized in 4 vol of 10 mM phosphate buffer (pH 3.5). After centrifugation at 20,000 g for 5 min, 400 μl of water were added to 100 μl of supernatant or serum and loaded onto a SAX cartridge (SUPELCO, Bellefonte, PA), previously conditioned with 0.5 ml of methanol and 1 ml of water. After elution, the cartridges were washed with 0.5 ml of 10 mM phosphate buffer (pH 3.5) and the eluates were collected. The so-obtained samples (1 ml) were used for the derivatization reaction. 1-Aminoantracene was dissolved in acetone (16 mg/ml) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) (Sigma; 1-mM stock in dimethyl sulfoxide) was added to each sample. The derivatization was completed after 7 days. The derivatized samples (50-μl injection) were separated on a Bio-Rad HPLC system with a Perkin-Elmer fluorescence detector (LS-1). The excitation and emission wavelengths were 310 and 420 nm, respectively.

Preparation of membranes from skeletal muscles and GLUT-4 determination. Muscles from rat hindlimb were removed and trimmed of connective tissue, fat, and nerves. The muscles were then minced and homogenized on ice three times using a Polytron homogenizer set at 13,500 rpm in a buffer containing 20 mM HEPES, 250 mM sucrose, 1 mM EDTA, 5 mM benzamidine, 1 μM aprotinin, 1 μM pepstatin, and 1 mM phenylmethylsulfonyl fluoride, pH 7.4. The homogenate was centrifuged at 2,000 g for 10 min. The pellet, which contained mainly unhomogenized pieces of tissue, was discarded, and the supernatant was centrifuged at 9,000 g for 20 min. The 9,000-g pellet (P1) was resuspended in PBS with the standard cocktail of protease inhibitors listed above. The supernatant was centrifuged at 180,000 g for 90 min. The 180,000-g pellet was resuspended in PBS with protease inhibitors, loaded on a 10–30% (wt/wt) continuous sucrose gradient (3–4 mg protein/5 ml gradient), and centrifuged at 48,000 rpm for 55 min in a SW-50.1 rotor. The pellet of the sucrose-gradient centrifugation (P2) was resuspended in PBS and analyzed for the presence of GLUT-4 by Western blotting. All centrifugations were performed at 4°C. Western blot was performed on 10% polyacrylamide gel (7). Anti-GLUT-4 polyclonal antibody (Santa Cruz Biotechnology) diluted 1:500 was used with anti-rabbit peroxidase conjugated antibody (Dako) diluted 1:3,000 and revealed by chemiluminescent substrate (Super Signal West Pico).

Indexes of liver function. We used AST and ALT as indexes of liver function. They were measured on plasma with immunoenzymatic method and read with a spectrophotometer at 340 nm.

In Vitro Study

Skeletal muscle cultures. Mouse myogenic C2C12 cell line was cultured in DMEM proliferating medium supplied with 10% fetal calf serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete medium) on flasks and on collagen-coated glass coverslips at the density of ~50,000 cells/cm². After 3 days of cell culture, fetal calf serum was substituted with 2% horse serum to induce myoblasts fusion and the myotube formation, which was completed after 7 days.

Cultured myotubes were treated with 1 μM staurosporine (Sigma; 1-mM stock in dimethyl sulfoxide) in fresh serum-containing DMEM and harvested for 18 h. Treatment of cultures with different concentrations of L-carnitine (2, 5, 10 mM) was initiated 1 h before staurosporine treatment and was maintained throughout the subsequent incubation. Control experiments were performed by adding only the vehicle each time (20, 26). Cell viability was analyzed by the colorimetric XTT assay (Cell Proliferation Kit II XTT, Roche). For this assay, equal numbers of C2C12 myogenic cells were plated on 96-well plates and maintained in the growing media to obtain myotubes. Differentiated myotubes were then incubated with staurosporine (added as a DMSO solution) either with or without L-carnitine. XTT reagents were eventually added to each well and incubated at 37°C for 4 h. After incubation, the plates were analyzed with a multiwell ELISA reader. Data were expressed as percentage of living cells.

Statistical analysis. Means ± SD are reported. Student’s t-test for unpaired data was used. P ≤ 0.05 was considered statistically significant. ANOVA was used when appropriate.

RESULTS

Occurrence of Heart Failure in the Monocrotaline-Treated Animals

After 4 wk, all the CHF rats showed the presence of pericardial, pleural, and peritoneal effusions at post-mortem examination (Table 1). RVM/LVM was 0.26 ±
Table 1. Cardiac and serum features in all rats

|                | RVM/RVV | RVM/LVM | ANG II,
pg/ml |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>6.0 ± 1.4bc</td>
<td>0.26 ± 0.09de</td>
<td>30 ± 10h</td>
</tr>
<tr>
<td>Carnitine</td>
<td>5.8 ± 1.7c</td>
<td>0.24 ± 0.1c</td>
<td>27 ± 9g</td>
</tr>
<tr>
<td>CHF</td>
<td>2.7 ± 0.7a,b</td>
<td>0.45 ± 0.09df</td>
<td>88 ± 2e,i</td>
</tr>
<tr>
<td>CHF + carnitine</td>
<td>3.4 ± 1.0c,e</td>
<td>0.43 ± 0.13ef</td>
<td>52 ± 23h,i</td>
</tr>
</tbody>
</table>

Values are means ± SE. CHF, congestive heart failure; RVM, right ventricle mass; RVV, right ventricle volume; LVM, left ventricle mass; ANG II, angiotensin II; RVM/RVV, *P < 0.0006; bp < 0.001; sp = not significant (NS). RVM/LVM: *P < 0.0006; *P < 0.00005. 

Table 2. Skeletal muscle features in all rats

<table>
<thead>
<tr>
<th></th>
<th>MHC IIA ( % of total)</th>
<th>MHC IIB ( % of total)</th>
<th>CSA, μm²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>25 ± 2.7a,b</td>
<td>76 ± 2.7</td>
<td>1,969 ± 257de</td>
</tr>
<tr>
<td>Carnitine</td>
<td>26 ± 1.7</td>
<td>74 ± 1.7</td>
<td>2,140 ± 340f</td>
</tr>
<tr>
<td>CHF</td>
<td>19 ± 3.6e</td>
<td>81 ± 3.6</td>
<td>1,281 ± 335df</td>
</tr>
<tr>
<td>CHF + carnitine</td>
<td>23 ± 3.2e</td>
<td>77 ± 3.2</td>
<td>1,558 ± 331f</td>
</tr>
</tbody>
</table>

Values are means ± SE. MHC, myosin heavy chain; CSA, cross-sectional area MHC IIA: *P < 0.04; *P = NS; *P < 0.04. CSA: *P < 0.01; *P < 0.004; *P = NS.

0.09 in control, 0.45 ± 0.09 in CHF (P < 0.0006), and 0.43 ± 0.13 in CHFCar [P = nonsignificant (NS) vs. CHF and P < 0.0001 vs. control]. The right ventricular cavity was markedly dilated in all the CHF rats as reflected by the RVM/RV index that was 2.7 ± 0.7 in the CHF rats vs. 6 ± 1.4 in the control group (P < 0.0006) and 3.4 ± 1 in the CHFCar group (P = NS vs. CHF and P < 0.001 vs. control).

ANG II Levels

ANG II levels were 30 ± 10 pg/ml in the control rats, which were the same of the ConCar rats (27 ± 9 pg/ml; Table 1). The CHF rats showed a significant (P < 0.008) increase in ANG II (88 ± 2), while L-carnitine produced a significant decrease in the ANG II levels in the ANG II levels were 30 ± 0.09 in control, 0.45 ± 0.09 in CHF (P < 0.0006), and 0.43 ± 0.13 in CHFCar [P = nonsignificant (NS) vs. CHF and P < 0.0001 vs. control].

MHC Pattern

We found a shift from the fast oxidative (MHC IIA) to the slow glycolytic isoform in the CHF animals (MHC IIB), which was 25 ± 2.7 and 76 ± 2.7% in the control vs. 19 ± 3.6 (P < 0.04) and 81 ± 3.6% in the CHF animals, respectively (Table 2). L-Carnitine produced a shift toward the MHC IIA (23 ± 3.2; P < 0.04), while MHC IIB was 77 ± 3.2%.

Tibialis Anterior CSA

The degree of muscle atrophy as measured by the tibialis anterior muscle CSA was 1,969 ± 257 μm² in the control vs. 1,281 ± 335 in the CHF rats (P < 0.01; Table 2). L-Carnitine treatment produced an increase in CSA (1,558 ± 331), which did not reach statistical significance (P = NS) compared with CHF rats. Despite this effect, there was still a significantly lower (P < 0.004) CSA vs. control rats.

Count of In Situ DNA TUNEL-Positive Nuclei

The CHF rats showed an enormous increase in the number of TUNEL-positive nuclei in the tibialis anterior muscle, which was 189 ± 27 nuclei/mm³, as opposed to 1 ± 1 of the control and ConCar animals (P < 0.0003; Table 1; Fig. 1A). The treatment with l-carnitine produced a significant reduction in the number of TUNEL-positive nuclei in the monocolateral-treated animals (56 ± 62; P < 0.001 vs. CHF and P < 0.02 vs. controls).

Activated Caspase-3 and -9, Bcl-2, and Confocal Microscopy for Caspase-3

We confirmed the occurrence of apoptosis in animals with a high number of TUNEL-positive nuclei by testing for the presence of activated caspase-3 and -9 (the mitochondrial regulator and the executioner, respectively) (Fig. 1, B, C, and D). Caspase-3 is detectable during the execution phase of apoptosis, when the caspase cascade leads inevitably to programmed cell death. The presence of activated caspase-3 (Fig. 1C) and -9 (Fig. 1D) was shown with immunoblotting and that of activated caspase-3 was shown with immunofluorescence and confocal microscopy (Fig. 1E). Higher levels of caspase-3 and -9 were present at immunoblotting (lanes c, d, and e in Fig. 1, C and D) in CHF animals, compared with controls (lanes a and b). The CHFCar animals (lanes f) showed a reduction on the expression of these two proapoptotic molecules, compared with CHF, although they did not reach the level of the control animals.

Bcl-2, that is an antiapoptotic factor, behaved in the opposite manner. It was decreased in CHF (Fig. 1B, lanes c and d) compared with control rats (lanes a and b). The CHFCar animals showed an expression of Bcl-2 similar to that of control animals (lanes e–i).

ELISA for Apoptosis

Evidence for apoptosis was also confirmed by detection of fragmented DNA by ELISA, where we found an increased optical density in the CHF rats compared with control. The CHFCar animals showed intermediate values (Fig. 2).

Table 3. Apoptotic cascade features in skeletal muscle and serum in all rats

<table>
<thead>
<tr>
<th></th>
<th>TUNEL+, nuclei/mm³</th>
<th>TNF-α, pg/ml</th>
<th>SPH, pmol/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1 ± 1bc</td>
<td>106 ± 59e</td>
<td>912 ± 145eh</td>
</tr>
<tr>
<td>Carnitine</td>
<td>1 ± 1</td>
<td>100 ± 35</td>
<td>843 ± 148</td>
</tr>
<tr>
<td>CHF</td>
<td>189 ± 27a,c</td>
<td>240 ± 86f,i</td>
<td>2250 ± 777e,i</td>
</tr>
<tr>
<td>CHF + carnitine</td>
<td>56 ± 62bc</td>
<td>150 ± 41f</td>
<td>1538 ± 409h,i</td>
</tr>
</tbody>
</table>

Values are means ± SE. TUNEL, in situ terminal transferase dUTP nick-end labeling; TNF-α, tumor necrosis factor; SPH, sphingosine. TUNEL+: *P < 0.0003; *P < 0.02; *P < 0.001. TNF-α: *P < 0.01; *P < 0.08; *P < 0.01. SPH: *P < 0.03; *P < 0.0005; *P < 0.05.
L-Carnitine Determination

In the serum of CHF animals, L-carnitine increased from 41.2 ± 9.9 to 67.5 ± 17 nm/ml compared with controls ($P < 0.006$). L-Carnitine treatment sorted out a further increase in L-carnitine serum levels both in normal and monocrotaline rats (182.5 ± 22.2 and 119.2 ± 12.7; Tables 4 and 5).

In the tibialis anterior muscle, CHF produced a dramatic decrease of L-carnitine, acetyl-carnitine, and propionyl-carnitine content compared with controls. L-Carnitine treatment restored almost normal values of the three carnitines in the tibialis anterior muscle (see Table 5).

TNF-α

There was, as expected, a rise in plasma levels of TNF-α in the CHF animals compared with control rats (240 ± 86 vs. 106 ± 59 pg/ml; $P < 0.01$; Table 3). L-Carnitine treatment produced a slight, though significant, decrease in TNF-α serum levels compared with CHF animals ($P < 0.01$); these values were not significantly different from those of control rats ($P = 0.08$).

SPH

SPH increased in CHF rats (2,250 ± 777 vs. 912 ± 145 pmol/ml in controls; $P < 0.03$; Table 3). L-Carnitine produced a small decrease in SPH serum levels (1,538 ± 409), which were significantly different from both CHF and control rats ($P < 0.05$ and $P < 0.0005$, respectively).

Effect of L-Carnitine on Staurosporine-Induced Apoptosis

Control myotubes showed 100% survival after 18 h in DMEM (Fig. 3). Staurosporine alone caused a drop
in skeletal myotuboe survival, which reached 79 ± 6% after the same incubation time.

1-Carnitine treatment was able to improve in a dose-dependent fashion the survival rate of the cultured myotubes. In fact after an 18-h incubation in staurosporine plus L-carnitine, the percentage of surviving cells was 86 ± 7, 94 ± 4, 100 ± 8% at the concentration of 2, 5, and 10 mM L-carnitine, respectively (P = NS for 2 mM L-carnitine vs. staurosporine and P < 0.01 for 5 and 10 mM, ANOVA).

Effect of L-Carnitine on GLUT-4 Expression

Previous studies (12, 37) have demonstrated, by Western blot analysis and enzymatic assay, that the pellet obtained from the supernatant of homogenized muscles after high-speed centrifugation in a continuous 10–30% sucrose gradient contains virtually all plasma membrane marker proteins, such as β1-integrin, none of which could be detected in the other gradient fractions. Thus the experimental conditions we used allowed us to separate the surface membranes from intracellular vesicles and to detect the insulin-dependent GLUT-4 translocation.

Figure 4 shows the Western blot analysis of GLUT-4 in muscle from control and treated animals. Monocrotaline injection induced a significant increase in GLUT-4 expression in the pellet fractions of the gradient (Fig. 4, lanes c, d, and e). This increase was present roughly to the same extent in the muscle plasma membrane fractions from rats treated with monocrotaline plus L-carnitine (Fig. 4, lanes f, g, and h).

Table 5. Muscle carnitine levels in all rats

<table>
<thead>
<tr>
<th></th>
<th>LC</th>
<th>ALC</th>
<th>PLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>716 ± 132*&lt;sup&gt;a,e&lt;/sup&gt;</td>
<td>234 ± 63*&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9 ± 2*&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Carnitine</td>
<td>809 ± 60</td>
<td>335 ± 32</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>CHF</td>
<td>334 ± 65*&lt;sup&gt;b&lt;/sup&gt;</td>
<td>150 ± 43*&lt;sup&gt;f&lt;/sup&gt;</td>
<td>1 ± 0.5*&lt;sup&gt;j&lt;/sup&gt;</td>
</tr>
<tr>
<td>CHF + carnitine</td>
<td>493 ± 163*&lt;sup&gt;c,e&lt;/sup&gt;</td>
<td>321 ± 133*&lt;sup&gt;f&lt;/sup&gt;</td>
<td>15 ± 4*&lt;sup&gt;j&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Values are means ± SE in nmol/gram wet tissue. LC: L-carnitine; ALC: acetyl-L-carnitine; PLC: propionyl-L-carnitine. LC: *P < 0.0001; <sup>a</sup>P < 0.001; <sup>b</sup>P < 0.01; ALC: <sup>f</sup>P < 0.06; *P = NS; <sup>j</sup>P < 0.04, PLC: <sup>c</sup>P < 0.004; <sup>b</sup>P = NS; <sup>j</sup>P < 0.003.

### DISCUSSION

We did not find any alteration in liver function enzymes in the monocrotaline-treated animals, compared with controls (AST 25.0 ± 2.3, 21.4 ± 4.1, ALT 73.8 ± 7.2 vs. 52.0 ± 17.4, P = NS).

In the rat, monocrotaline induces right ventricle hypertrophy followed by right ventricle dilatation and failure. In these animals, we found skeletal muscle atrophy secondary to myocyte nuclei apoptosis and shift of MHCs toward the fast glycolytic isoforms, confirming previously published data (7, 28, 34). The presence of CHF is supported, beyond the postmortem findings of pleural, pericardial, and peritoneal effusions, by the right ventricle dilatation, as indicated by the decreased RVM/RVV index (7, 28, 34) and by the elevated plasma levels of ANG II (4, 6).

The occurrence of apoptosis in our study was confirmed by different techniques, including immunoblotting, immunohistochemistry, confocal microscopy, and ELISA of DNA ladder. Activated caspase-3 and -9 were also present; this ensured that the caspase cascade,
L-carnitine, beyond the well-known metabolic impairement and to the lower levels of apoptosis observed in the CHFCar animals.

Metabolic Impairment

In the CHF rats, we have shown a profoundly altered glucose metabolism; in fact, after monocrotaline treatment, skeletal muscle GLUT-4 expression dramatically increases. The contemporary administration of L-carnitine does not counterbalance the monocrotaline-induced GLUT-4 overexpression, therefore, suggesting that L-carnitine does not play a role in modulating insulin responsiveness of skeletal muscles in monocrotaline-treated rats.

In a mouse model of skeletal muscle GLUT-4 overexpression, it was demonstrated that the increased glycolysis in muscle was associated both with increased serum lactate levels and with increased flux of this metabolite through the Cori cycle (27).

The glycolysis rates were increased in these animals, whereas their glucose oxidation rates seemed to be considerably lower than of glycolysis (probably secondary to inhibition of pyruvate dehydrogenase complex by acetyl-CoA derived from increased substrate oxidation). By a parallelism between our model and the transgenic model, it is possible to postulate that L-carnitine could have an important role in regulating glucose metabolism in skeletal muscle of monocrotaline-treated rats. This has been also shown in the rat perfused heart, where physiological concentrations of carnitine mimic insulin-like metabolic effects by increasing glucose oxidation (24).

By increasing muscle L-carnitine levels in the CHF, rats may stimulate glucose oxidation by the action of L-carnitine on inner mitochondrial L-carnitine acetyltransferase, which enhances conversion of mitochondrial acetyl-CoA to cytoplasmic acetylcarnitine, resulting in a decrease in the inner mitochondrial acetyl-CoA ratio. A decrease in this ratio will stimulate the pyruvate dehydrogenase complex, the enzyme that converts pyruvate to acetyl-CoA and is the rate-limiting step of glucose oxidation. As a result of an increase of L-carnitine in muscle overexpressing GLUT-4, a greater proportion of the pyruvate derived from glycolysis, as well as pyruvate derived from lactate, can be oxidized.

The reported changes in HMC composition after L-carnitine treatment can be due as well to the well-known trophic metabolic effect of L-carnitine on type IIa skeletal muscle fibers (11).

Apoptosis

In the L-carnitine-treated CHF rats, we found a substantially lower degree of TUNEL-positive nuclei and DNA break strands (ELISA ladder), which were accompanied by a lower expression of caspases and by an increased expression of Bel-2. We can speculate on the mechanisms by which L-carnitine may have prevented apoptosis: 1) by blocking TNF-α and sphingolipids activation cascade as previously shown in the heart (2), and 2) by inhibiting the cleavage of caspases substrates at mitochondrial level, making it a general caspase inhibitor (21). The partially reduced levels of TNF-α and SPH found in this study may have blunted the phospholipid-induced apoptosis.

In this study, the mitochondrial pathway is certainly involved, in that activated caspase-3 and -9 are inhibited and Bcl-2 is increased. In vitro inhibition of staurosporine-induced apoptosis, which in C2C12 cells acts via the mitochondrial cascade (20, 26), strengthens this hypothesis. It is not surprising that L-carnitine may be active at the mitochondrial level in that it accumulates at this site. It has been recently suggested by Andrieu-Abadie et al. (2) that ceramide generation is linked to mitochondrial metabolism. If that were the case, we would not be dealing with two so independent pathways. It is hard to split the beneficial effects of L-carnitine between its action on myocyte metabolism and its role in modulating apoptosis. We cannot also exclude indirect effects on TNF-α, SPH, and ANG II downregulation. The complexity of the interplay between these molecules has been previously shown by our group in the same animal model; ANG II receptor blockade was in fact able to decrease not only apoptosis but also TNF-α (4) and SPH (5).

We know that skeletal muscle bulk is one of the major determinants of exercise capacity, in that muscle
L-CARNITINE PREVENTS SKELETAL MUSCLE APOPTOSIS

AJP-Cell Physiol • VOL 283 • SEPTEMBER 2002 • www.ajpcell.org

strength is related to bulk (18, 35). Muscle waste is also linked to prognosis; patients with cardiac cachexia, in whom muscle waste is extreme, have a very poor prognosis (3). It is therefore clear how blocking apoptosis and improving oxidative metabolism may prevent skeletal muscle bulk loss and improve exercise capacity and maybe prognosis in the CHF patients.

The clinical relevance of these findings may be speculated. In agreement with previous studies carried out in patients with CHF, muscle levels of L-carnitine are decreased (19) and plasma levels are increased (8), confirming a muscle deficiency and a reduced uptake of L-carnitine both in humans and in our animal model of CHF. It is clear that interventions trying to restore normal levels of carnitine at muscle level have the potential for improving skeletal muscle metabolism and also trophism. Although a large randomized trial with L-carnitine on exercise capacity (9) has been published, it has shown neutral results on the long-term outcome. Only in a subgroup of patients with preserved ejection fraction and in another small study were there partially positive effects of the active treatment on peak oxygen consumption (1). We think that a conclusive interpretation cannot be drawn yet. Our data show only a partial improvement in preventing apoptosis, atrophy, cytokine release, and SPH formation. In overt heart failure, if production of cytokines and sphingolipids is overwhelming, as it is in sickest or cachectic patients, the consequent apoptosis may be only partially modulated. It is therefore possible that intervention may be effective only in well-defined subgroups of patients. However, it is important to understand the mechanisms by which L-carnitine is acting so that they may shed some light on the pathophysiology of the CHF myopathy and possibly lead to the prevention of atrophy, the preservation of exercise capacity, and the design of clinical trials targeted on particular populations, which look not only at clinical but even at biological end points.

REFERENCES


